The Saudi Genome Program (SGP), inaugurated in 2018 by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz, Crown Prince and Prime Minister, represents a distinctive national initiative that harnesses state-of-the-art genomic technologies to effectively reduce the occurrence of genetic diseases. The SGP will drive advancements in healthcare by enhancing diagnosis, therapy, and prevention.
In 2022, the first phase of strategy development was set in motion, unveiling the ambitious roadmap for SGP 2.0. This transformative vision aims to position the Kingdom as a renowned global frontrunner in genomics, achieved through a series of audacious yet attainable objectives. These include establishing the Kingdom as a global hub for world-class collaborations on prevalent genetic diseases, becoming a leader in genetics and genomics within the MENA region, and ensuring genomics plays a vital role in delivering high-quality healthcare to all Saudi citizens. With SGP, the future of healthcare is set to be revolutionized in the most extraordinary way.
Learn more about how Vision 2030 and the Health Sector Transformation Program are positioning the Kingdom as a global leader in healthcare.